ArticleCureus2025
Central Retinal Artery Occlusion After Intravitreal Injection of Faricimab: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Faricimab: current evidence for the treatment of retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Pooled it
- Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Faricimab is a relatively novel agent as a bispecific antibody that inhibits both vascular endothelial growth factor-A and angiopoietin-2. Although it's effective for several retinal diseases, several rare adverse events, such as retinal vasculitis, have been reported. We present a case of central retinal artery occlusion (CRAO) following intravitreal injection of faricimab in a 74-year-old woman treated for central retinal vein occlusion. A sudden decrease in visual acuity occurred 24 hours after the second injection. Her best-corrected visual acuity was counting fingers at 30 cm. No anterior chamber inflammation was observed. Fundus examination showed retinal whitening at the posterior pole. Optical coherence tomography revealed intraretinal edema, and fluorescein angiography showed mild perfusion delay without leakages from retinal vessels. She was diagnosed with CRAO. After one month, her vision remained at 0.01. This case highlights that CRAO may occur as a rare but serious vascular adverse event following faricimab injection. Ophthalmologists should be aware of this potential complication and counsel patients accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.